Boothbay Fund Management, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Boothbay Fund Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $221,533 - $420,332	-52,872 Reduced 81.54%	11,968 $72,000
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $91,131 - $143,923	-20,073 Reduced 23.64%	64,840 $302,000
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $6,820 - $10,302	1,421 Added 1.7%	84,913 $599,000
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $381,558 - $599,472	83,492 New	83,492 $493,000
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $109,147 - $807,124	-28,350 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $453,883 - $983,461	28,350 New	28,350 $815,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.